These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37461974)

  • 1. P056 Real life experience with the use of tofacitinib in ulcerative colitis in Colombia: case series.
    Parra Izquierdo V; Frias-Ordoñez J; Galindo P; Romero-Sanchez C; Florez C
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S14-S15. PubMed ID: 37461974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: Real world experience.
    Parra-Izquierdo V; Frías-Ordoñez JS; Márquez JR; Juliao-Baños F; Galindo P; Cuadros C; Rojas C; Rojas N; Ardila O; Tovar-Fierro G; García-Duperly R; Vargas M; Flórez-Sarmiento C
    Gastroenterol Hepatol; 2023; 46(7):512-521. PubMed ID: 36372256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
    Chiorean M; Daperno M; Lees CW; Bonfanti G; Soudis D; Modesto I; Deuring JJ; Edwards RA
    Adv Ther; 2023 Oct; 40(10):4440-4459. PubMed ID: 37525075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study.
    Shin SH; Oh K; Hong SN; Lee J; Oh SJ; Kim ES; Na SY; Kang SB; Koh SJ; Bang KB; Jung SA; Jung SH; Kim KO; Park SH; Yang SK; Choi CH; Ye BD
    Therap Adv Gastroenterol; 2023; 16():17562848231154103. PubMed ID: 36950251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombian pediatric patients: Real world experience.
    Parra-Izquierdo V; Frías-Ordoñez JS; Cuadros C; Vargas M; Vera Chamorro JF; Romero Sanchez C; Flórez-Sarmiento C
    Gastroenterol Hepatol; 2024; 47(6):574-581. PubMed ID: 37820832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study.
    Carvalhas Gabrielli AM; Ferretti F; Monico CM; Tombetti E; Maconi G; Romeo S; Piazza O Sed N; Caprioli F; Mazzola AM; Alicante S; Bertè R; Lolli E; Scribano ML; Buscarini E; Ricci C; Carmagnola S; Ardizzone S; Cannatelli R
    Dig Dis Sci; 2024 May; 69(5):1785-1792. PubMed ID: 38530500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
    Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
    Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P004 Steroid-Free Remission in Patients With Ulcerative Colitis Receiving Tofacitinib in Real Clinical Practice.
    Knyazev O; Kagramanova A; Lishchinskaya A; Babayan A; Kulakov D; Li I; Shkurko T
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S1. PubMed ID: 37461925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
    Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
    J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience.
    Kotwani P; Terdiman J; Lewin S
    J Crohns Colitis; 2020 Jul; 14(7):1026-1028. PubMed ID: 32020189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel.
    Avni-Biron I; Bar-Gil Shitrit A; Koslowsky B; Levartovsky A; Kopylov U; Weisshof R; Aviv Cohen N; Maharshak N; Hovel D; Israeli E; Naftali T; Goren I; Snir Y; Ollech JE; Banai-Eran H; Broitman Y; Sharar-Fischler T; Dotan I; Yanai H
    Dig Liver Dis; 2022 Feb; 54(2):192-197. PubMed ID: 34887214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis.
    Straatmijer T; van Gennep S; Duijvestein M; Ponsioen CIJ; Gecse KB; D'Haens GR; Löwenberg M
    Eur J Gastroenterol Hepatol; 2021 Oct; 33(10):1288-1297. PubMed ID: 33405424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colombian experience with the use of tofacitinib in severe acute ulcerative colitis: A case series study.
    Parra-Izquierdo V; Frías-Ordoñez JS; Juliao-Baños F; Cuadros C; Romero Sanchez C; Flórez-Sarmiento C
    Gastroenterol Hepatol; 2024; 47(6):582-590. PubMed ID: 37806342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
    Biemans VBC; Sleutjes JAM; de Vries AC; Bodelier AGL; Dijkstra G; Oldenburg B; Löwenberg M; van Bodegraven AA; van der Meulen-de Jong AE; de Boer NKH; Srivastava N; West RL; Römkens TEH; Horjus Talabur Horje CS; Jansen JM; van der Woude CJ; Hoekstra J; Weersma RK; van Schaik FDM; Hoentjen F; Pierik MJ;
    Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort.
    Dalal RS; Sharma PP; Bains K; Pruce JC; Allegretti JR
    Inflamm Bowel Dis; 2024 Oct; 30(10):1707-1713. PubMed ID: 37843044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study.
    Straatmijer T; Biemans VBC; Visschedijk M; Hoentjen F; de Vries A; van Bodegraven AA; Bodelier A; de Boer NKH; Dijkstra G; Festen N; Horjus C; Jansen JM; Jharap B; Mares W; van Schaik FDM; Ponsioen C; Romkens T; Srivastava N; van der Voorn MMPJA; West R; van der Woude J; Wolvers MDJ; Pierik M; van der Meulen-de Jong AE; Duijvestein M;
    Clin Gastroenterol Hepatol; 2023 Jan; 21(1):182-191.e2. PubMed ID: 35644343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom.
    Lindsay JO; Picker N; Kromer D; Smyth M; Patel H
    Curr Med Res Opin; 2023 May; 39(5):681-689. PubMed ID: 36951899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabis for the treatment of ulcerative colitis.
    Kafil TS; Nguyen TM; MacDonald JK; Chande N
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012954. PubMed ID: 30406638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.